Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity initiated with a Neutral at Mizuho
Mizuho initiated coverage of Doximity with a Neutral rating and $55 price target. The company has witnessed some volatility in quarterly top-line growth over the past few years due to timing of pharma digital ad spending within the Doximity physician user app, including decelerating top-line growth throughout much of FY24, the analyst tells investors in a research note. Mizuho adds that it remains confident in Doximity's ability to generate low double-digit annual revenue growth over the next few years, but also believes that there may be better entry points into the stock.
Are Medical Stocks Lagging Doximity (DOCS) This Year?
Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year.
Dr Martens redemption arc will be ‘multi-year event'
The post-IPO narrative surrounding footwear icon Dr Martens PLC (LSE:DOCS) has been so overwhelmingly negative that it's easy to glance over the green shoots of optimism emerging from the business. While plummeting revenues in the first half filtered through to a pre-tax loss, analysts from broker Peel Hunt noted that the numbers were broadly in line with forecasts.
Dr Martens shares booted higher despite swinging to a loss
Dr Martens PLC (LSE:DOCS)'s double-digit revenue decline and pre-tax loss in the first half wasn't as bad as it seems, if the market's reaction is anything to go by. Shares in the shoe brand, which has struggled to grow its US sales volumes, added more than 12% following publication of the results.
Dr Martens delivers double-digit sales decline and jumbo pre-tax loss
Dr Martens PLC (LSE:DOCS) had another unflattering trading performance in the first half of its financial year, with revenues declining 18% year-on-year to £325 million, in line with expectations. The iconic footwear group saw £29 million in losses before tax compared to last year's £26 million profit.
Dr Martens set to unveil loss as all eyes on outlook in results
Dr Martens PLC (LSE:DOCS)'s first half results on Thursday, 28 November will likely be more about its outlook as a decline in sales and swing to loss are expected. According to Deutsche Bank analysts, revenue is set to have fallen by 18% over the first half, pushing the shoemaker to a “well-flagged” pre-tax loss of £34 million.
3 Momentum Anomaly Stocks to Buy as Election Rally Fizzles
DOCS, PI and INOD are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Surging Earnings Estimates Signal Upside for Doximity (DOCS) Stock
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Doximity Q2 Earnings: Positioning Is Paying Off
I rate Doximity a buy with a price target of $65, reflecting a 24% upside due to strong Q2 earnings and favorable industry trends. Doximity's Q2 earnings showed impressive revenue growth, margin expansion, and a revised forecast of 36% CAGR in revenue and 74% CAGR in Adjusted EBITDA. Positioned at the intersection of healthcare trends, Doximity offers cost-saving solutions that align with industry needs, supporting double-digit growth through 2030.
Dr. Martens upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Louise Singlehurst upgraded Dr. Martens to Neutral from Sell with a price target of 64 GBp, down from 71 GBp. The firm sees emerging valuation support post the recent de-rating of the shares. It expects Dr. Martens' EBIT margins to inflect positively into fiscal 2026 post three years of margin compression.
Why Doximity Stock Is Skyrocketing Today
The market loved what it saw from Doximity's second-quarter earnings.
Why Doximity Stock is Set to Open at Highest Point in Over 2 Years Friday
Doximity (DOCS) shares jumped nearly 40% in premarket trading Friday after the medical tech company's earnings and outlook came in above what analysts expected.
